The invention provides a compound of Formula (I)
or a pharmaceutically acceptable salt thereof; wherein
G is
R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS
申请人:Pfizer Inc.
公开号:EP2699576A1
公开(公告)日:2014-02-26
PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL-COA CARBOXYLASE INHIBITORS
申请人:Pfizer Inc.
公开号:EP2699576B1
公开(公告)日:2015-12-09
US8802688B2
申请人:——
公开号:US8802688B2
公开(公告)日:2014-08-12
[EN] PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLOSPIROCÉTONE DESTINÉS À ÊTRE UTILISÉS COMME INHIBITEURS D'ACÉTYL-COA CARBOXYLASE
申请人:PFIZER
公开号:WO2012143813A1
公开(公告)日:2012-10-26
The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is (II) or (III) R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.